Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis

[1]  T. Dawber,et al.  The Framingham Study , 2014 .

[2]  R. Henry,et al.  Efficacy and safety of initial combination treatment with sitagliptin and pioglitazone—a factorial study , 2014, Diabetes, obesity & metabolism.

[3]  S. Inzucchi,et al.  Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function , 2013, Diabetes, obesity & metabolism.

[4]  Y. Shentu,et al.  Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes. , 2013, Journal of diabetes and its complications.

[5]  M. Monami,et al.  Dipeptidyl peptidase‐4 inhibitors and cardiovascular risk: a meta‐analysis of randomized clinical trials , 2013, Diabetes, obesity & metabolism.

[6]  Y. Shentu,et al.  The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes *† , 2012, Journal of diabetes.

[7]  J. Rosenstock,et al.  2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial , 2012, The Lancet.

[8]  K. Yoon,et al.  Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54‐week study , 2012, Diabetes, obesity & metabolism.

[9]  G. Chrysant,et al.  Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors. , 2012, The American journal of cardiology.

[10]  S. Engel,et al.  Initial therapy with the fixed‐dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes , 2012, Diabetes, obesity & metabolism.

[11]  N. Marx,et al.  Potential cardiovascular effects of incretin-based therapies , 2012, Expert review of cardiovascular therapy.

[12]  P. Light,et al.  Variations in tissue selectivity amongst insulin secretagogues: a systematic review , 2012, Diabetes, obesity & metabolism.

[13]  Michael E. Cobble,et al.  Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data , 2012, Cardiovascular Diabetology.

[14]  H. Woerle,et al.  Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme , 2012, Cardiovascular Diabetology.

[15]  Y. Birnbaum,et al.  The potential effects of anti-diabetic medications on myocardial ischemia–reperfusion injury , 2011, Basic Research in Cardiology.

[16]  B. Goldstein,et al.  A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents , 2011, Diabetes, obesity & metabolism.

[17]  B. Goldstein,et al.  Efficacy and safety of sitagliptin and the fixed‐dose combination of sitagliptin and metformin vs. pioglitazone in drug‐naïve patients with type 2 diabetes , 2011, International journal of clinical practice.

[18]  J. Jansson,et al.  The disparity between long-term survival in patients with and without diabetes following a first myocardial infarction did not change between 1989 and 2006: an analysis of 6,776 patients in the Northern Sweden MONICA Study , 2011, Diabetologia.

[19]  B. Goldstein,et al.  The effect of initial therapy with the fixed‐dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus , 2011, Diabetes, obesity and metabolism.

[20]  D. Drucker,et al.  The safety of incretin-based therapies--review of the scientific evidence. , 2011, The Journal of clinical endocrinology and metabolism.

[21]  N. Barzilai,et al.  Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial , 2011, Current medical research and opinion.

[22]  B. Dokken,et al.  Glucagon-like Peptide-1 (GLP-1), Immediately Prior to Reperfusion, Decreases Neutrophil Activation and Reduces Myocardial Infarct Size in Rodents , 2011, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[23]  K. Kaufman,et al.  Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double‐blind, non‐inferiority trial , 2011, Diabetes, obesity & metabolism.

[24]  G. Golm,et al.  Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase‐4 inhibitor, and pioglitazone on glycemic control and measures of β‐cell function in patients with type 2 diabetes , 2011, International journal of clinical practice.

[25]  M. Reiser,et al.  Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI-Trial)--rationale, design and first interim analysis. , 2010, International journal of cardiology.

[26]  A. Vaag,et al.  Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention - a retrospective nationwide cohort study , 2010, Cardiovascular diabetology.

[27]  S. Dejager,et al.  Assessing the cardio–cerebrovascular safety of vildagliptin: meta‐analysis of adjudicated events from a large Phase III type 2 diabetes population , 2010, Diabetes, obesity & metabolism.

[28]  G. Golm,et al.  Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes , 2010, Diabetes, obesity & metabolism.

[29]  Yu Lin,et al.  The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA. , 2010, American journal of physiology. Heart and circulatory physiology.

[30]  B. Goldstein,et al.  Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes , 2010, BMC endocrine disorders.

[31]  M. Davies,et al.  Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2‐year study , 2010, International journal of clinical practice.

[32]  A. Avogaro,et al.  The Oral Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Increases Circulating Endothelial Progenitor Cells in Patients With Type 2 Diabetes , 2010, Diabetes Care.

[33]  K. Kaufman,et al.  Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes , 2010, Diabetes, obesity & metabolism.

[34]  D. Dutka,et al.  DPP-4 Inhibition by Sitagliptin Improves the Myocardial Response to Dobutamine Stress and Mitigates Stunning in a Pilot Study of Patients With Coronary Artery Disease , 2010, Circulation. Cardiovascular imaging.

[35]  Masafumi Takahashi.  Role of the SDF-1/CXCR4 system in myocardial infarction. , 2010, Circulation journal : official journal of the Japanese Circulation Society.

[36]  J. Rosenstock,et al.  Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes , 2010, Diabetes, obesity & metabolism.

[37]  R. Henkelman,et al.  Genetic Deletion or Pharmacological Inhibition of Dipeptidyl Peptidase-4 Improves Cardiovascular Outcomes After Myocardial Infarction in Mice , 2010, Diabetes.

[38]  P. Elliott,et al.  Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database , 2009, BMJ : British Medical Journal.

[39]  Robert David,et al.  Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction. , 2009, Cell stem cell.

[40]  R. Califf,et al.  Rationale and design of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) , 2009 .

[41]  V. Mohan,et al.  Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. , 2009, Diabetes research and clinical practice.

[42]  Edmund Luo,et al.  Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. , 2009, Current medical research and opinion.

[43]  Anil Jain,et al.  The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis , 2009, Acta Diabetologica.

[44]  M. Davies,et al.  Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes * , 2008, Diabetes, obesity & metabolism.

[45]  K. Reynolds,et al.  Is the Combination of Sulfonylureas and Metformin Associated With an Increased Risk of Cardiovascular Disease or All-Cause Mortality? , 2008, Diabetes Care.

[46]  B. Frier,et al.  Vascular disease and diabetes: is hypoglycaemia an aggravating factor? , 2008, Diabetes/metabolism research and reviews.

[47]  R. Holt,et al.  The Effect of Sulphonylureas on the Microvascular and Macrovascular Complications of Diabetes , 2008, Cardiovascular Drugs and Therapy.

[48]  J. Leahy.  Effect of Initial Combination Therapy With Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, and Metformin on Glycemic Control in Patients With Type 2 Diabetes , 2008 .

[49]  Tara Gomes,et al.  Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. , 2007, JAMA.

[50]  R. Rizza,et al.  Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. , 2007, American journal of physiology. Endocrinology and metabolism.

[51]  Yoon K Loke,et al.  Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. , 2007, JAMA.

[52]  K. Hermansen,et al.  Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin , 2007, Diabetes, obesity & metabolism.

[53]  S. Nissen,et al.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.

[54]  M. Hanefeld,et al.  Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes* , 2007, Current medical research and opinion.

[55]  M. Nauck,et al.  Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial , 2007, Diabetes, obesity & metabolism.

[56]  P. Stein,et al.  Efficacy and tolerability of the dipeptidyl peptidase‐4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes , 2006, International journal of clinical practice.

[57]  B. Zinman,et al.  Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. , 2006, The New England journal of medicine.

[58]  D. Drucker,et al.  The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes , 2006, The Lancet.

[59]  Ronald Brazg,et al.  Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. , 2006, Clinical therapeutics.

[60]  M. Hanefeld,et al.  Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus , 2006, Diabetologia.

[61]  J. Tayek.  Comment on: Evans JMM, Ogston SA, Emslie-Smith A, Morris AD (2006) Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49:930–936 , 2006, Diabetologia.

[62]  A. Morris,et al.  Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin , 2006, Diabetologia.

[63]  S. Majumdar,et al.  Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[64]  M. Mocanu,et al.  Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. , 2005, Diabetes.

[65]  Neil J Stone,et al.  Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.

[66]  R. Shannon,et al.  Effects of Glucagon-Like Peptide-1 in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction After Successful Reperfusion , 2004, Circulation.

[67]  M. Nauck,et al.  Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important? , 2003, Heart.

[68]  S. Majumdar,et al.  Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. , 2002, Diabetes care.

[69]  S. Inzucchi.  Oral antihyperglycemic therapy for type 2 diabetes: scientific review. , 2002, JAMA.

[70]  J. Muller,et al.  Impact of diabetes on long-term survival after acute myocardial infarction: comparability of risk with prior myocardial infarction. , 2001, Diabetes care.

[71]  P. Simpson,et al.  Statistical methods in cancer research , 2001, Journal of surgical oncology.

[72]  R. Holman,et al.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.

[73]  Teven,et al.  MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .

[74]  C. Conti.  Cardiovascular diabetology. , 1999, Clinical cardiology.

[75]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[76]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[77]  Uk-Prospective-Diabetes-Study-Group.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[78]  V. Salomaa,et al.  Impact of Diabetes on Mortality After the First Myocardial Infarction , 1998, Diabetes Care.

[79]  J Col,et al.  Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. , 1995, Circulation.

[80]  J. Neaton,et al.  Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial , 1993, Diabetes Care.

[81]  P. Wilson,et al.  The impact of diabetes on survival following myocardial infarction in men vs women. The Framingham Study. , 1988, JAMA.

[82]  N. Breslow,et al.  Statistical methods in cancer research. Volume II--The design and analysis of cohort studies. , 1987, IARC scientific publications.

[83]  N Breslow,et al.  Estimators of the Mantel-Haenszel variance consistent in both sparse data and large-strata limiting models. , 1986, Biometrics.

[84]  American diabetes association policy statement: the UGDP controversy. , 1979, Diabetes care.

[85]  H. Seltzer.  A Summary of Criticisms of the Findings and Conclusions of the University Group Diabetes Program (UGDP) , 1972, Diabetes.

[86]  C. Meinert,et al.  A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. , 1970, Diabetes.